RxDoctor Payments Data

David Schulze, NP

Family · Edmond, OKNPI 1447766407

Payments from drug & device makers

$3,064in general payments, 2019–2025

Across 50 payments — averaging $61.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • GSK$636
  • AbbVie$336
  • Janssen Scientific Affairs, LLC$316
  • Novartis$169
  • AstraZeneca$157
  • plus $325 from 6 others

What the payments were for

  • Food & beverage$3,064100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen12$1,124
GSK10$636
AbbVie4$336
Janssen Scientific Affairs, LLC3$316
Novartis4$169
AstraZeneca4$157
Johnson & Johnson3$144
Surmodics, Inc.6$100
UCB, Inc.1$29
Organon1$22
Boston Scientific1$15
Tonix Medicines, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,064 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$73,266
Medicare patients
232
Services billed
3,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab54$538,168
Enbrel SureclickEtanercept52$402,304
RemicadeInfliximab40$337,470
Simponi AriaGolimumab21$188,568
RinvoqUpadacitinib25$156,079
BenlystaBelimumab26$152,979
Orencia ClickjectAbatacept26$146,652
Xeljanz XrTofacitinib Citrate20$109,454
Actemra ActpenTocilizumab18$84,924
Hydroxychloroquine Sulfate493$18,664
Celecoxib218$8,102
MethotrexateMethotrexate Sodium244$5,787
Pilocarpine Hcl33$3,875
Leflunomide71$3,514
Sulfasalazine DrSulfasalazine119$3,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRemicade, Simponi Aria$144$526,03861 claims
AbbVieRinvoq$336$156,07925 claims
GSKBenlysta$636$152,97926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.

Other family in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →